ArriVent BioPharma, Inc.
AVBP · XNASCIK 1868279fmd_1GASWE70R6VEA55K777EXB4910Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 65 | 79 | 153 |
| Total operating expenses | 75 | 94 | 178 |
| Operating income | (75) | (94) | (178) |
| Net income | (69) | (80) | (166) |
| Net income to common shareholders | (69) | (80) | (166) |